SG11201810927QA - Pd-l1-specific antibodies and methods of using the same - Google Patents
Pd-l1-specific antibodies and methods of using the sameInfo
- Publication number
- SG11201810927QA SG11201810927QA SG11201810927QA SG11201810927QA SG11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA SG 11201810927Q A SG11201810927Q A SG 11201810927QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- control mab
- pct
- antibodies
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013642 negative control Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356105P | 2016-06-29 | 2016-06-29 | |
| PCT/US2017/039810 WO2018005682A2 (fr) | 2016-06-29 | 2017-06-28 | Anticorps spécifiques de pd-l1 et procédés pour les utiliser |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810927QA true SG11201810927QA (en) | 2019-01-30 |
Family
ID=60785529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810927QA SG11201810927QA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
| SG10202100100UA SG10202100100UA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100100UA SG10202100100UA (en) | 2016-06-29 | 2017-06-28 | Pd-l1-specific antibodies and methods of using the same |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10590199B2 (fr) |
| EP (1) | EP3478723A4 (fr) |
| JP (2) | JP7148414B2 (fr) |
| KR (2) | KR102422411B1 (fr) |
| CN (1) | CN109641960A (fr) |
| AU (1) | AU2017290709A1 (fr) |
| BR (1) | BR112018076684A2 (fr) |
| CA (1) | CA3027204A1 (fr) |
| IL (2) | IL263611B (fr) |
| MX (1) | MX2018016183A (fr) |
| RU (1) | RU2749109C2 (fr) |
| SG (2) | SG11201810927QA (fr) |
| WO (1) | WO2018005682A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102422411B1 (ko) * | 2016-06-29 | 2022-07-18 | 체크포인트 테라퓨틱스, 인크. | Pd-l1-특이적 항체 및 이를 사용하는 방법 |
| WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| JP7092404B2 (ja) * | 2018-10-31 | 2022-06-28 | イミュニティーバイオ、インコーポレイテッド | Ｐｄ－ｌ１キメラ抗原受容体を発現するｎｋ細胞によるｐｄ－ｌ１陽性悪性腫瘍の排除 |
| KR102207478B1 (ko) * | 2019-03-13 | 2021-01-26 | 한국도로공사 | 시간 정보를 활용한 톨링 시스템 및 그의 구동 방법 |
| JP7212990B2 (ja) * | 2019-04-26 | 2023-01-26 | アイ－エムエービー バイオファーマ ユーエス リミテッド | ヒトｐｄ‐ｌ１抗体 |
| AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
| CN113121686A (zh) * | 2019-12-31 | 2021-07-16 | 迈威(上海)生物科技股份有限公司 | 抗pd-l1抗体及其应用 |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (fr) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Polythérapies utilisant un agoniste de tlr7/8 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP5396080B2 (ja) | 2005-06-30 | 2014-01-22 | アッヴィ・インコーポレイテッド | ＩＬ−１２／ｐ４０結合蛋白質 |
| KR101888321B1 (ko) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| AU2006308648A1 (en) | 2005-10-31 | 2007-05-10 | Duke University | Antibodies and immunotoxins that target human glycoprotein NMB |
| GB0914691D0 (en) * | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| WO2011066389A1 (fr) * | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Agents de liaison ciblés dirigés contre b7-h1 |
| CA2856895C (fr) * | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anticorps anti-pd-l1 et utilisations associees |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
| KR20170090506A (ko) | 2014-12-19 | 2017-08-07 | 다나-파버 캔서 인스티튜트 인크. | 키메라 항원 수용체 및 이의 사용 방법 |
| SG11201707383PA (en) * | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| JP7022993B2 (ja) * | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の４１ｂｂ結合融合タンパク質 |
| CA3026151A1 (fr) * | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de controle bispecifiques |
| KR102422411B1 (ko) * | 2016-06-29 | 2022-07-18 | 체크포인트 테라퓨틱스, 인크. | Pd-l1-특이적 항체 및 이를 사용하는 방법 |
| JP2019526595A (ja) * | 2016-09-09 | 2019-09-19 | ティージー セラピューティクス，インコーポレイテッド | 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ |
-
2017
- 2017-06-28 KR KR1020217041795A patent/KR102422411B1/ko active IP Right Grant
- 2017-06-28 SG SG11201810927QA patent/SG11201810927QA/en unknown
- 2017-06-28 RU RU2019102009A patent/RU2749109C2/ru active
- 2017-06-28 MX MX2018016183A patent/MX2018016183A/es unknown
- 2017-06-28 BR BR112018076684-4A patent/BR112018076684A2/pt unknown
- 2017-06-28 SG SG10202100100UA patent/SG10202100100UA/en unknown
- 2017-06-28 JP JP2018567904A patent/JP7148414B2/ja active Active
- 2017-06-28 CN CN201780045033.XA patent/CN109641960A/zh active Pending
- 2017-06-28 CA CA3027204A patent/CA3027204A1/fr active Pending
- 2017-06-28 WO PCT/US2017/039810 patent/WO2018005682A2/fr unknown
- 2017-06-28 KR KR1020197002192A patent/KR20190028716A/ko not_active Application Discontinuation
- 2017-06-28 US US15/636,610 patent/US10590199B2/en active Active
- 2017-06-28 EP EP17821178.5A patent/EP3478723A4/fr active Pending
- 2017-06-28 AU AU2017290709A patent/AU2017290709A1/en active Pending
-
2018
- 2018-12-10 IL IL263611A patent/IL263611B/en active IP Right Grant
-
2020
- 2020-03-13 US US16/818,621 patent/US11834505B2/en active Active
- 2020-08-05 IL IL276515A patent/IL276515A/en unknown
-
2022
- 2022-06-07 JP JP2022092210A patent/JP2022120008A/ja active Pending
-
2023
- 2023-10-06 US US18/377,702 patent/US20240150468A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3027204A1 (fr) | 2018-01-04 |
| MX2018016183A (es) | 2019-06-10 |
| US20240150468A1 (en) | 2024-05-09 |
| RU2749109C2 (ru) | 2021-06-04 |
| AU2017290709A1 (en) | 2019-01-24 |
| SG10202100100UA (en) | 2021-02-25 |
| KR20220004763A (ko) | 2022-01-11 |
| EP3478723A4 (fr) | 2020-07-29 |
| WO2018005682A2 (fr) | 2018-01-04 |
| US10590199B2 (en) | 2020-03-17 |
| IL276515A (en) | 2020-09-30 |
| US20200277380A1 (en) | 2020-09-03 |
| IL263611A (en) | 2019-01-31 |
| KR20190028716A (ko) | 2019-03-19 |
| BR112018076684A2 (pt) | 2019-04-02 |
| RU2019102009A (ru) | 2020-07-28 |
| US11834505B2 (en) | 2023-12-05 |
| RU2019102009A3 (fr) | 2020-12-14 |
| JP2019532013A (ja) | 2019-11-07 |
| JP7148414B2 (ja) | 2022-10-05 |
| JP2022120008A (ja) | 2022-08-17 |
| US20180002424A1 (en) | 2018-01-04 |
| EP3478723A2 (fr) | 2019-05-08 |
| IL263611B (en) | 2020-08-31 |
| CN109641960A (zh) | 2019-04-16 |
| KR102422411B1 (ko) | 2022-07-18 |
| WO2018005682A3 (fr) | 2018-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau |